Home 2017-05-08T02:45:42+00:00

Novel cancer therapies targeting key cancer pathways

READ MORE
Prescient Therapeutics PTX

We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.

prescient therapeutics

OUR COMPANY

Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Read more

prescient therapeutics

OUR SCIENCE

Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.

Read more

prescient therapeutics

LATEST NEWS

21/10/2017Edison Investment Research –
Clinical Development Update
PDF
20/11/2017Results of Annual General MeetingPDF
20/11/2017AGM Chairman AddressPDF
20/11/2017AGM PresentationPDF
06/11/2017PTX to resume Clinical Trial of PTX-200 in Ovarian CancerPDF
27/10/2017September 2017 Appendix 4C - QuarterlyPDF